Overnutrition causes hyperactivation of mTORC1-dependent negative feedback loops leading to the downregulation of insulin signaling and development of insulin *** osteoblasts(OBs),insulin signaling plays a crucial rol...
详细信息
Overnutrition causes hyperactivation of mTORC1-dependent negative feedback loops leading to the downregulation of insulin signaling and development of insulin *** osteoblasts(OBs),insulin signaling plays a crucial role in the control of systemic glucose *** utilized mice with conditional deletion of Rptor to investigate how the loss of mTORC1 function in OB affects glucose metabolism under normal and overnutrition dietary *** to the controls,chow-fed Rptorob−/−mice had substantially less fat mass and exhibited adipocyte ***,upon feeding with high-fat diet,mice with pre-and post-natal deletion of Rptor in OBs were protected from diet-induced obesity and exhibited improved glucose metabolism with lower fasting glucose and insulin levels,increased glucose tolerance and insulin *** leanness and resistance to weight gain was not attributable to changes in food intake,physical activity or lipid absorption but instead was due to increased energy expenditure and greater whole-body substrate ***-seq revealed an increase in glycolysis and skeletal insulin signaling pathways,which correlated with the potentiation of insulin signaling and increased insulin-dependent glucose uptake in Rptorknockout ***,these findings point to a critical role for the mTORC1 complex in the skeletal regulation of wholebody glucose metabolism and the skeletal development of insulin resistance.
Colorectal cancer remains one of the most common cancers worldwide and,despite improvements in treatment options for late-stage metastatic cancer,there are still questionssurrounding how best to treat early-stage dis...
详细信息
Colorectal cancer remains one of the most common cancers worldwide and,despite improvements in treatment options for late-stage metastatic cancer,there are still questions surrounding how best to treat early-stage disease *** recent advances have been made in the staging of cancer and improving the risk assessment of strategies for patient treatment.A number of high-risk features have been proposed that may help to stratify stage Ⅱ cancer patients into groups that will truly benefit from adjuvant *** tests are becoming available to measure these biomarkers,utilizing both currently available and novel *** review will describe the challenges in treatment decisions for early-stage colon cancer and how personalized medicine can assist clinicians in making the best treatment choices for patients with stage Ⅱ colon cancer in particular.
暂无评论